Targeted treatments in autism and fragile X syndrome
Year: 2012
Type: article
Source: Research in Autism
Authors: C. Kağan Gürkan, Randi J. Hagerman
Institution: University of California Davis Medical Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: autism spectrum disorder, fragile X syndrome, fragile X premutation, fragile X-associated tremor/ataxia syndrome, mGluR5 antagonist, GABA-B receptor agonist, targeted therapy, genetic etiology of autism, Rett syndrome, tuberous sclerosis complex, Asperger syndrome, pervasive developmental disorders
Open Access status: green
Funders: National Institutes of Health, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Center for Research Resources, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6), Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 of, Neuro Therapeutics Research Institute (1 of 6), UC Davis Clinical and Translational Science Center, Genetics and Physiology of Social Anxiety in Fragile X, Research in Intellectual and Developmental Disabilities, Interdisciplinary Training Program in Neurotherapeutics (6 of 6), Genotype-Phenotype Relationships in Fragile X Families
OpenAlex ID: W2058438630
